Producer

Shenguan Holdings (Group)

0829.HKHQ CN · Guangxi Province, China (operations); Hong Kong (holding)website ↗

Dominant Chinese collagen casing manufacturer; 80% of China's domestic collagen casing market. Listed on Hong Kong Stock Exchange. Founded 1989 in Guangxi. Also manufactures pharmaceutical products, skin care products, health care products for pregnant women and toddlers, and bioactive collagen products from the same bovine collagen source as its sausage casings. The company that makes 80% of China's sausage casings also makes Chinese pharmaceutical-grade collagen and maternal health products — all from the same Guangxi slaughterhouse-sourced bovine corium.

2

Inputs supplied

1

Goods downstream

2

Facilities

0

Stories

What they make

2 inputs Shenguan Holdings (Group) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where it shows up

Goods downstream

Essential goods that depend on something Shenguan Holdings (Group) makes, pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map, where this supply-chain role fits within their broader business.

  • Edible Collagen Casings

    90%
  • Medical-Grade Collagen (Victory Biotech subsidiary)

  • Medical Device Pipeline (Class III pending NMPA)

  • Consumer Health & Skincare

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

  • Did you know2024

    Shenguan Holdings — which controls 80% of China's collagen sausage casing market — simultaneously manufactures pharmaceutical-grade collagen products, skin care products, health care products for pregnant women and toddlers, and bioactive collagen supplements, all from the same bovine corium collagen sourced from Guangxi slaughterhouses. The molecule that gives a Chinese breakfast sausage its casing is chemically identical to the collagen in a maternal health supplement or a dermal filler precursor. Shenguan processes this versatility from the same Guangxi facility, making it simultaneously the dominant player in the Chinese meat processing supply chain and a healthcare/cosmetics materials company.

    Shenguan Holdings
  • Capacity2023

    Shenguan's Victory Biotech subsidiary has a collagen bone filler material (artificial bone substitute) in clinical trials at 7 hospitals in China, awaiting NMPA Class III medical device approval — typically a 2-4 year process. Victory Biotech's atelocollagen meets or exceeds US FDA endotoxin standards at 0.01 EU/ml (50x below the 0.5 EU/ml FDA limit), enabling export qualification for US and European medical device markets. If the bone filler obtains NMPA approval, it would enter a premium hospital market currently dominated by Shandong Biomaterials (China) and international players like Geistlich (Switzerland).

    Victory Biotech Co., Ltd.
  • Origin2023

    Shenguan Holdings was founded in 1989 in Guangxi, China, as a collagen casing manufacturer using bovine corium (cattle hide splits) sourced from local slaughterhouses. After building a dominant 80% share of China's domestic collagen casing market over three decades, Shenguan pivoted in 2015 by acquiring Guangdong Victory Biotech — an ISO 13485-certified medical collagen producer. The company's declared 'One Body, Three Wings' strategy uses the same bovine corium supply to feed four verticals: sausage casings (body), consumer food, skincare, and biomedical collagen (three wings). The biomedical wing is generating its first commercial revenue while absorbing losses ahead of NMPA medical device approvals.

    Shenguan Holdings (Group) Limited